8/13/2019 Wilson s Disease
1/28
Medical GeneticsAutosomal Recessive
DisorderWILSONS DISEASE/HEPATOLENTICULAR
DEGENERATION
8/13/2019 Wilson s Disease
2/28
Plan Of Presentation
Overview of the Disease
-Background
-Etiology
-Epidemiology
-Prognosis
Clinical Presentations
Workup Of the Disease
Treatment And Management
8/13/2019 Wilson s Disease
3/28
Background of the disease
Wilson disease is a rare autosomal recessive inherited disorder of copper m
The condition is characterized by excessive deposition of copper in the livother tissues. The major physiologic aberration is excessive absorption of csmall intestine and decreased excretion of copper by the liver.
The genetic defect, localized to arm 13q, has been shown to affect the cotransporting adenosine triphosphatase (ATPase) gene (ATP7B) in the liver.
8/13/2019 Wilson s Disease
4/28
Copper metabolism in Wilson s dis
8/13/2019 Wilson s Disease
5/28
Etiology of disease
The normal estimated total body copper content is 50-100 mg, and the avintake 2-5 mg, depending on an individuals food intake.
Impairment of incorporation of copper into ceruloplasmin and excretion ointo bile. (defective copper-transporting P-type ATPase. )
mutations in the ATP7B gene
8/13/2019 Wilson s Disease
6/28
Epidemiology
In the United States, the carrier frequency is 1 per 90 individuals. The prevWilson disease is 1 per 30,000 individuals.
The fulminant presentation of Wilson disease is more common in females males.
Age-related presentations
-In general, the upper age limit for considering Wilson Disease is 40 years and
age limit is 5 years, although the disorder has been detected in children youyears and in adults older than 70 years.
8/13/2019 Wilson s Disease
7/28
Prognosis
Score 0 1 2 3 4
Serum bilirubin(referencerange, 3-20mmol/L)
< 100 100-150 151-200 201-300 >300
Serumaspartatetransaminase(referencerange, 7-40IU/L)
< 100 100-150 151-200 201-300 >300
Prothrombintimeprolongation(seconds)
< 4 4-8 9-12 13-20 >30
Table. Prognostic Index in Fulminant Wilsonian Hepatitis
Patients with a prognostic index (ie, score) of 7 or greater should be considered for livtransplantation. All patients in the study associated with this prognostic index who excdied within 2 months of diagnosis, irrespective of the institution of appropriate medica
8/13/2019 Wilson s Disease
8/28
Prognosis after liver transplantation is relatively good.
In a study involving 55 patients with Wilson disease who underwent hepatransplantation, the 1-year survival rate was 79% and the overall survival at 3 months to 20 years.
8/13/2019 Wilson s Disease
9/28
Complications
The major complications in patients with untreated Wilson disease are thwith acute liver failure, chronic hepatic dysfunction with either portal hyphepatocellular carcinoma.
sometimes-relentless course to cirrhosis, which is characterized by a proglassitude, fatigue, anorexia, jaundice, spider angiomas, splenomegaly, a
Bleeding from varices, hepatic encephalopathy, hepatorenal syndromecoagulation abnormalities occur as liver failure ensues.
8/13/2019 Wilson s Disease
10/28
Staging
The natural history of Wilson disease may be considered in 4 stages, as follow
Stage I - The initial period of accumulation of copper within hepatic bind
Stage II - The acute redistribution of copper within the liver and its releasecirculation
Stage III - The chronic accumulation of copper in the brain and other exttissue, with progressive and eventually fatal disease
Stage IV - Restoration of copper balance by the use of long-term chelati
8/13/2019 Wilson s Disease
11/28
Clinical Presentations
Physical Examinations
Hepatic dysfunction is the presenting feature in more than half of patients. Thpatterns of hepatic involvement are as follows: (1) chronic active hepatitis, (2(3) fulminant hepatic failure.
1. Neuropsychiatric symptoms
Asymmetrical tremor
Frequent early symptoms(difficulty speaking, excessive salivation, ataxia, m
clumsiness with the hands, and personality changes.)
Late manifestations (dystonia, spasticity, grand mal seizures, rigidity, and flecontractures.)
8/13/2019 Wilson s Disease
12/28
8/13/2019 Wilson s Disease
13/28
2. Musculoskeletal symptoms
arthropathy generally involves the spine and large appendicular joints, sucwrists, and hips.
Osteochondritis dissecans Chondromalacia patellae
Chondrocalcinosis
8/13/2019 Wilson s Disease
14/28
3. Hematologic symptoms
Hemolytic anemia
Coombs-negative acute intravascular hemolysis (oxidative damage to thby the higher copper concentration.)
4. Renal symptoms
Any renal manifestations may be primary or secondary to release of copper
defective renal acidification and excess renal losses of amino acids, glucgalactose, pentose, uric acid, phosphate, and calcium.
Urolithiasis
Hematuria
Nephrocalcinosis
8/13/2019 Wilson s Disease
15/28
Hepatic symptoms
Hepatic insufficiency and cirrhosis may
slowly develop and can result in signs of
fulminant hepatic failure, including thefollowing:
Ascites and prominent abdominal veins
Spider nevi
Palmar erythema
Digital clubbing
Hematemesis
Jaundice
8/13/2019 Wilson s Disease
16/28
Neurologic symptoms
Central nervous system (CNS) pathology in
patients with Wilson disease results from
copper deposition in the basal ganglia. Theresulting signs include the following:
Drooling
Dysphagia
Dystonia
IncoordinationDifficulty with fine motor tasks
Masklike facies
Gait disturbance
8/13/2019 Wilson s Disease
17/28
Ophthalmologic symptoms
-Kayser-Fleischer rings are formed by the
deposition of copper in the Descemet
membrane in the limbus of the cornea. The
color may range from greenish gold to brown.
-almost invariably present in those withneurologic manifestations.
-Kayser-Fleischer rings consist of electron-
dense granules rich in copper and sulfur. The
rings form bilaterally, initially appearing at thesuperior pole of the cornea, then the inferior
pole, and, ultimately, circumferentially.
8/13/2019 Wilson s Disease
18/28
Additional symptoms
Osteoporosis
Osteomalacia
Rickets
Spontaneous fractures
Polyarthritis
Cardiac arrhythmia
Skin pigmentation
Bluish discoloration at the base of the fingernails (azure lunulae)
8/13/2019 Wilson s Disease
19/28
Diagnostic Considerations
-Conditions to consider in the differential diagnosis of Wilson disease might include the following
Autoimmune chronic active hepatitis
Aceruloplasminemia
Glycogen-storage disease Cirrhosis
Multiple sclerosis
Huntington disease
Depression
Antisocial personality disorder
Parkinson disease
Leukodystrophy
CNS vasculitis
Neurodegenerative disease
1-antitrypsin deficiency
Chronic anemia
Hereditary hemochromatosis
Workup and Diagnosis
8/13/2019 Wilson s Disease
20/28
Workup and Diagnosis
1. Genetic diagnosis
Linkage analysis has been used in family studies for presymptomatic testingthe multiplicity of mutations (>200 mutations of ATP7Bhave been identified
2. Computed tomography (CT) scanning, magnetic resonance imaging (MRI)ultrasonography
3. Electrocardiography
Resting electrocardiographic abnormalities include left ventricular or bivenhypertrophy, early repolarization, ST segment depression, T-wave inversion,arrhythmias.
8/13/2019 Wilson s Disease
21/28
4. Serum Ceruloplasmin
Approximately 90% of all patients with Wilson disease have ceruloplasmin than 20 mg/dL (reference range, 20-40 mg/dL).
5. Urinary copper excretion
The urinary copper excretion rate is greater than 100 mcg/d (reference rangmcg/d) in most patients with symptomatic Wilson disease.
6. Hepatic copper concentration
A liver biopsy with sufficient tissue reveals levels of more than 250 mcg/g.
(reference range, 15-55 mcg/g)
8/13/2019 Wilson s Disease
22/28
7. Radiolabeled Copper
Radiolabeled copper testing directly assays hepatic copper metabolism. Blo1, 2, 4, 24, and 48 hours after oral ingestion of radiolabeled copper (64Cu or67
radioactivity in serum.
8. Cranial CT Scanning
The cranial lesions observed on CT scans are typically bilaterainto 2 general categories:
(1) well-defined, slitlike, low-attenuation foci involving the basparticularly the putamen
(2) (2) larger regions of low attenuation in the basal ganglia, tdentate nucleus.
9 B i MRI
8/13/2019 Wilson s Disease
23/28
9. Brain MRI
10. PET Scanning
-reveals a significantly reduced regional cerebral metabolic rate of glucose the cerebellum, striatum, and, to a lesser extent, in the cortex and thalamus.
11. Electron Microscopy
12. Histological Findings
Treatment and Management
8/13/2019 Wilson s Disease
24/28
Treatment and Management
The mainstay of therapy for Wilson disease is pharmacologic treatment wagents.
The use of surgical decompression or transjugular intrahepatic shunting (T
treatment of portal hypertension is reserved for individuals with recurrent ovariceal bleeding that is unresponsive to standard conservative measures
Orthotopic liver transplantation
Diet
-avoid eating foods with a high copper content, such as liver, chocolate, nulegumes, and shellfish (especially lobster).
8/13/2019 Wilson s Disease
25/28
Long-Term Monitoring
-Perform a physical examination, 24-hour urinary copper excretion assay, cblood count (CBC), urinalysis, serum free copper measurement, and renal function tests on a weekly basis for the first 4-6 weeks following initiation of
therapy.
Molecular Adsorbents Recirculating System (MARS)
- MARS is an extracorporeal liver support system using a hollow-fiber dialysis
which the patients blood is dialyzed across an albumin-impregnated memmaintaining a constant flow of albumin-rich (20%) dialysate in the extracapcompartment
8/13/2019 Wilson s Disease
26/28
M di ti
8/13/2019 Wilson s Disease
27/28
Medications
1) Chelators
Penicillamine (Cuprimine, Depen)- administered with pyridoxine 25 mg by mouth daily.
Trientine (Syprine)
2) Nutrients
Zinc (Galzin)Pyridoxine (Aminoxin, Pyri-500)
http://reference.medscape.com/drug/cuprimine-depen-penicillamine-343728http://reference.medscape.com/drug/cuprimine-depen-penicillamine-343728http://reference.medscape.com/drug/syprine-trientin-trientine-342888http://reference.medscape.com/drug/galzin-zinc-344449http://reference.medscape.com/drug/vitamin-b6-nestrex-pyridoxine-344425http://reference.medscape.com/drug/vitamin-b6-nestrex-pyridoxine-344425http://reference.medscape.com/drug/vitamin-b6-nestrex-pyridoxine-344425http://reference.medscape.com/drug/vitamin-b6-nestrex-pyridoxine-344425http://reference.medscape.com/drug/vitamin-b6-nestrex-pyridoxine-344425http://reference.medscape.com/drug/vitamin-b6-nestrex-pyridoxine-344425http://reference.medscape.com/drug/galzin-zinc-344449http://reference.medscape.com/drug/galzin-zinc-344449http://reference.medscape.com/drug/galzin-zinc-344449http://reference.medscape.com/drug/syprine-trientin-trientine-342888http://reference.medscape.com/drug/syprine-trientin-trientine-342888http://reference.medscape.com/drug/syprine-trientin-trientine-342888http://reference.medscape.com/drug/syprine-trientin-trientine-342888http://reference.medscape.com/drug/syprine-trientin-trientine-342888http://reference.medscape.com/drug/cuprimine-depen-penicillamine-343728http://reference.medscape.com/drug/cuprimine-depen-penicillamine-343728http://reference.medscape.com/drug/cuprimine-depen-penicillamine-343728http://reference.medscape.com/drug/cuprimine-depen-penicillamine-343728http://reference.medscape.com/drug/cuprimine-depen-penicillamine-343728http://reference.medscape.com/drug/cuprimine-depen-penicillamine-343728http://reference.medscape.com/drug/cuprimine-depen-penicillamine-343728http://reference.medscape.com/drug/cuprimine-depen-penicillamine-343728http://reference.medscape.com/drug/cuprimine-depen-penicillamine-343728http://reference.medscape.com/drug/cuprimine-depen-penicillamine-343728http://reference.medscape.com/drug/cuprimine-depen-penicillamine-3437288/13/2019 Wilson s Disease
28/28
The End
Top Related